NLS Pharmaceutics Changes EGM Record Date

Ticker: NCEL · Form: 6-K · Filed: Oct 1, 2024 · CIK: 1783036

Nls Pharmaceutics LTD. 6-K Filing Summary
FieldDetail
CompanyNls Pharmaceutics LTD. (NCEL)
Form Type6-K
Filed DateOct 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$1 b, $2,500,000, $1.00
Sentimentneutral

Sentiment: neutral

Topics: meeting-update, corporate-governance

Related Tickers: NLS

TL;DR

NLS Pharma pushed back EGM record date to Sept 9 due to invite delays.

AI Summary

NLS Pharmaceutics Ltd. announced on September 27, 2024, that it has changed the record date for its extraordinary general meeting. The meeting, originally scheduled for October 3, 2024, now has a new record date of September 9, 2024, 11:59 p.m. CET, moved from the previous September 10, 2024, record date. This adjustment was necessitated by a delay in the distribution and publication of the meeting's invitation.

Why It Matters

This change in record date could affect which shareholders are eligible to vote at the upcoming extraordinary general meeting, potentially influencing the outcome of any decisions made.

Risk Assessment

Risk Level: low — The filing is a procedural update regarding a meeting date, with no immediate financial or operational impact disclosed.

Key Players & Entities

FAQ

What is the new record date for NLS Pharmaceutics' extraordinary general meeting?

The new record date is September 9, 2024, 11:59 p.m. CET.

Why was the record date changed?

The record date was changed due to a delay in the dispatch and publication of the invitation for the Meeting.

What was the original record date?

The original record date was September 10, 2024, 11:59 p.m. CET.

When is the extraordinary general meeting now scheduled to take place?

The extraordinary general meeting is scheduled to take place on October 3, 2024.

Who made the decision to change the record date?

The Board of Directors of NLS Pharmaceutics Ltd. amended the record date.

Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-10-01 16:01:13

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 1, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing